The Treatment of Hemophilia

Publisher Website
Google Scholar
Abstract
Concentrated preparations of factor VIII became commercially available in 1965 and were soon widely used in the United States and throughout the world to treat hemophilia. The development of these concentrates represented a tremendous therapeutic advance. The enthusiasm that greeted them was only mildly dampened by the early realization that all factor VIII products were contaminated with hepatitis viruses and by the resulting epidemic of hepatitis B and non-A, non-B hepatitis among people with hemophilia. Although 90 percent of the patients severely affected with hemophilia eventually became seropositive for hepatitis B antibody and although non-A, non-B hepatitis was thought to . . .